177 related articles for article (PubMed ID: 34268530)
1. An update on acalabrutinib to treat chronic lymphocytic leukemia.
Blackmon A; O'Brien S
Drugs Today (Barc); 2021 Jul; 57(7):417-431. PubMed ID: 34268530
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells.
Patel V; Balakrishnan K; Bibikova E; Ayres M; Keating MJ; Wierda WG; Gandhi V
Clin Cancer Res; 2017 Jul; 23(14):3734-3743. PubMed ID: 28034907
[No Abstract] [Full Text] [Related]
3. Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging Data.
Isaac K; Mato AR
Cancer Manag Res; 2020; 12():2079-2085. PubMed ID: 32256115
[TBL] [Abstract][Full Text] [Related]
4. Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial.
Seymour JF; Byrd JC; Ghia P; Kater AP; Chanan-Khan A; Furman RR; O'Brien S; Brown JR; Munir T; Mato A; Stilgenbauer S; Bajwa N; Miranda P; Higgins K; John E; de Borja M; Jurczak W; Woyach JA
Blood; 2023 Aug; 142(8):687-699. PubMed ID: 37390310
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy.
Patel VK; Lamothe B; Ayres ML; Gay J; Cheung JP; Balakrishnan K; Ivan C; Morse J; Nelson M; Keating MJ; Wierda WG; Marszalek JR; Gandhi V
Leukemia; 2018 Apr; 32(4):920-930. PubMed ID: 29099493
[TBL] [Abstract][Full Text] [Related]
6. Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: Pooled analysis of 5 clinical trials.
Davids MS; Sharman JP; Ghia P; Woyach JA; Eyre TA; Jurczak W; Siddiqi T; Palhares de Miranda PA; Shahkarami M; Butturini AM; Emeribe U; Byrd JC
Blood Adv; 2024 Apr; ():. PubMed ID: 38640349
[TBL] [Abstract][Full Text] [Related]
7. Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice.
O'Brien SM; Brown JR; Byrd JC; Furman RR; Ghia P; Sharman JP; Wierda WG
Front Oncol; 2021; 11():720704. PubMed ID: 34858810
[TBL] [Abstract][Full Text] [Related]
8. Invasive Aspergillosis with impaired neutrophil responses against Aspergillus fumigatus in patients treated with Acalabrutinib-findings from three cases.
Blaize M; Thizy G; Boissonnas A; Portalier A; Lanternier F; de La Porte des Vaux C; Suarez F; Bougnoux ME; Guitard J; Jabet A; Stocker N; Aoudjhane A; Roos-Weil D; Fekkar A
Int J Infect Dis; 2024 May; 142():107000. PubMed ID: 38461932
[TBL] [Abstract][Full Text] [Related]
9. MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Ryan CE; Davids MS; Hermann R; Shahkarami M; Biondo J; Abhyankar S; Alhasani H; Sharman JP; Mato AR; Roeker LE
Future Oncol; 2022 Oct; 18(33):3689-3699. PubMed ID: 36102212
[TBL] [Abstract][Full Text] [Related]
10. Mutational profile of previously treated chronic lymphocytic leukemia patients progressing on acalabrutinib or ibrutinib.
Woyach JA; Jones D; Jurczak W; Robak T; Illes A; Kater AP; Ghia P; Byrd JC; Seymour JF; Long S; Mohamed N; Benrashid S; Lai TH; De Jesus G; Lai R; de Bruin G; Rule S; Munugalavadla V
Blood; 2024 May; ():. PubMed ID: 38754046
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Bruton tyrosine kinase inhibitors monotherapy and combination therapy in lymphocytic leukemia.
Liu X; Hu B; Peng N; Chen L; Hu D; Zhang J; Wang L; Xie Z; Niu S; Lu Q; Lu J; Fang Y
Clin Exp Med; 2023 Dec; 23(8):4237-4248. PubMed ID: 37831432
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Ibrutinib-Based Regimen in Chronic Lymphocytic Leukemia: A Systematic Review.
Sardar M; Malik SU; Khan A; Idrees M; Ahmad Q; Sohail C; Naseer R; Amin S; McBride A; Abuzar M; Safdar A; Chakraborty R; Lee P; Sharon D; Anwer F
J Hematol; 2019 Mar; 8(1):1-10. PubMed ID: 32300434
[TBL] [Abstract][Full Text] [Related]
13. CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy.
Alsadhan A; Chen J; Gaglione EM; Underbayev C; Tuma PL; Tian X; Freeman LA; Baskar S; Nierman P; Soto S; Itsara A; Ahn IE; Sun C; Bibikova E; Hartmann TN; Mhibik M; Wiestner A
Clin Cancer Res; 2023 Sep; 29(18):3612-3621. PubMed ID: 37227160
[TBL] [Abstract][Full Text] [Related]
14. An indirect comparison of acalabrutinib with and without obinutuzumab versus zanubrutinib in treatment-naive CLL.
Kittai AS; Allan JN; James D; Bridge H; Miranda M; Yong AS; Fam F; Roos J; Shetty V; Skarbnik AP; Davids MS
Blood Adv; 2024 Apr; ():. PubMed ID: 38598745
[TBL] [Abstract][Full Text] [Related]
15. Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukaemia: Dead Yet, or Alive and Kicking?
Smolej L; Vodárek P; Écsiová D; Šimkovič M
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34201565
[TBL] [Abstract][Full Text] [Related]
16. Treatment of relapsed/refractory chronic lymphocytic leukemia with Zanubrutinib after progressing on other BTK inhibitors.
Nwankwo N; Reddy A; Kumar S; Zafar M
Leuk Res Rep; 2024; 21():100459. PubMed ID: 38660617
[TBL] [Abstract][Full Text] [Related]
17. Six-year update of the ELEVATE-TN study on acalabrutinib.
Sharman J
Clin Adv Hematol Oncol; 2024 Apr; 22(3):121-122. PubMed ID: 38588270
[No Abstract] [Full Text] [Related]
18. Effective treatment of pleural effusion in chronic lymphocytic leukemia with acalabrutinib: a case report.
Kurosawa S; Yokota T; Takada Y; Okubo S; Masuda M; Nakayama H; Sakurai A; Ito C; Aisa Y; Nakazato T
Ann Hematol; 2024 May; 103(5):1779-1781. PubMed ID: 38512464
[No Abstract] [Full Text] [Related]
19. CNS Aspergillosis and Cryptococcosis with Cytomegalovirus Pneumonia in a Patient with Chronic Lymphocytic Leukemia Treated with Acalabrutinib.
Fallin T; Thacker E; Sahra S; Siegrist EA; White BP; Summers K; Shibib D; Sassine J
J Pharm Pract; 2024 Apr; ():8971900241247660. PubMed ID: 38621678
[TBL] [Abstract][Full Text] [Related]
20. Emergence of overt myeloma in a patient with chronic lymphocytic leukemia on ibrutinib therapy.
Al-Katib AM; Gaith H; Sano D; Al-Katib S; Bonnett M; Kafri Z
Clin Case Rep; 2020 Sep; 8(9):1797-1801. PubMed ID: 32983498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
